ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 233 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $12,076,495 | -11.9% | 293,832 | +0.1% | 1.65% | -14.5% |
| Q1 2024 | $13,705,569 | +42.6% | 293,544 | +46.0% | 1.93% | +24.5% |
| Q4 2023 | $9,613,924 | +4.1% | 201,044 | -22.4% | 1.55% | -8.1% |
| Q3 2023 | $9,238,163 | +9.0% | 259,135 | +41.1% | 1.68% | +27.2% |
| Q2 2023 | $8,473,896 | +15.0% | 183,696 | 0.0% | 1.32% | +7.5% |
| Q1 2023 | $7,366,210 | -13.4% | 183,696 | 0.0% | 1.23% | -32.6% |
| Q4 2022 | $8,510,636 | +18.3% | 183,696 | +5.8% | 1.83% | +83.1% |
| Q3 2022 | $7,193,000 | +46.4% | 173,696 | +51.0% | 1.00% | +146.4% |
| Q4 2019 | $4,912,000 | -4.4% | 115,000 | +9.5% | 0.40% | -69.6% |
| Q2 2016 | $5,136,000 | +73.7% | 105,000 | +242.0% | 1.33% | +253.6% |
| Q3 2015 | $2,957,000 | -39.5% | 30,700 | -35.6% | 0.38% | -21.1% |
| Q2 2015 | $4,884,000 | – | 47,700 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
| Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
| Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
| AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
| EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
| FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
| HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
| Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |